Aaron Goldberg

11PUBLICATIONS
64CO-AUTHORS
Medical infection agents (incl. prions)Medical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Dec 06, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Kuo-Kai Chin, Brian J Ball, Yasmin Abaza

|Oct 14, 2024
HMA/VEN treatment modifications and associated outcomes in <i>IDH</i>-mutant AML.

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare

|Jun 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.

Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis

|Jun 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignancies.

Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi

|Feb 07, 2024
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.

Eunice S Wang, Aaron D Goldberg, Martin Tallman

|Sep 20, 2023
Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.

Troy M Robinson, Robert L Bowman, Sonali Persaud

Pageof 2